Trials / Completed
CompletedNCT02209584
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 274 (actual)
- Sponsor
- Myriad Genetic Laboratories, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This registry is intended to measure the impact of Prolaris® testing on therapeutic decisions when added to standard clinical-pathological parameters in men with newly diagnosed prostate cancer.
Conditions
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-04-15
- Completion
- 2015-12-08
- First posted
- 2014-08-06
- Last updated
- 2017-09-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02209584. Inclusion in this directory is not an endorsement.